GlycoPEG-GCSF

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
GlycoPEG-GCSF
Accession Number
DB06022
Type
Biotech
Groups
Investigational
Description

GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.

Pharmacodynamics
Not Available
Mechanism of action

GlycoPEG-GCSF is a long-acting, GlycoPEGylated granulocyte colony stimulating factor for the treatment of neutropenia. G-CSF is prescribed to stimulate the production of neutrophils, and is approved for sale in major markets around the world for the treatment of neutropenia associated with myelosuppressive chemotherapy. Neutropenia is a severe reduction in the number of neutrophils (mature white blood cells) in the circulating blood, commonly associated with cancer chemotherapy. Patients with neutropenia are at increased risk of developing serious infection. If not treated promptly, neutropenia can be life-threatening.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with GlycoPEG-GCSF.
Antihemophilic Factor (Recombinant), PEGylatedThe therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with GlycoPEG-GCSF.
Cepeginterferon alfa-2BThe therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with GlycoPEG-GCSF.
Certolizumab pegolThe therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with GlycoPEG-GCSF.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with GlycoPEG-GCSF.
Egaptivon pegolThe therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Egaptivon pegol.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with GlycoPEG-GCSF.
Eptacog alfa pegol (activated)The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with GlycoPEG-GCSF.
Heptaethylene glycolThe therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Heptaethylene glycol.
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with GlycoPEG-GCSF.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:29 / Updated on August 02, 2019 07:48